Investigation Of A Novel Cardiotoxicity Evaluation Method Using iPS-Derived Cardiomyocytes

Evaluating drug-induced cardiotoxicity early in development is critical for patient safety, yet traditional methods like calcium transient imaging often struggle to detect subtle metabolic shifts. While these established tests effectively capture immediate electrophysiological changes, they can overlook long-term impacts on cellular health. Recent research demonstrates that monitoring glucose consumption and lactate production in human iPS-derived cardiomyocytes provides a more nuanced view of drug impact.

Using a live cell metabolic pathway analyzer reveals how substances like Doxorubicin cause a delayed, sharp decline in metabolic rates after an initial period of compensated glycolysis. This continuous tracking identifies toxicity at lower concentrations than conventional imaging by visualizing the progression from mitochondrial stress to eventual cell dysfunction. Integrating metabolic flux analysis into safety protocols offers a sophisticated, longitudinal perspective on how therapeutics alter cardiac energy metabolism. Explore the full study to see how real-time metabolic monitoring can refine your cardiotoxicity screening.